Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors

Fineline Cube Apr 14, 2026
Company Deals

Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M

Fineline Cube Apr 14, 2026
Company Deals

Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration

Fineline Cube Apr 14, 2026
Company Deals

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

Fineline Cube Apr 13, 2026
Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History

Fineline Cube Apr 14, 2026
Company Drug

Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years

Fineline Cube Apr 14, 2026
Company Deals

Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies

Fineline Cube Dec 4, 2023

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration...

Company Deals

Concentra Biosciences Targets China-Based Biotech LianBio in Unsolicited Takeover Bid

Fineline Cube Dec 4, 2023

LianBio (OTCMKTS: LIANY), a China-based biotech firm, has become the target of an unsolicited takeover...

Medical Device Policy / Regulatory

FDA Investigates Safety of China-Made Plastic Syringes Due to Quality Concerns

Fineline Cube Dec 4, 2023

The US Food and Drug Administration (FDA) has issued a warning that it is investigating...

Policy / Regulatory

China’s State Council Unveils Comprehensive Plan to Boost Beijing’s Healthcare Sector

Fineline Cube Dec 1, 2023

The State Council has unveiled a comprehensive “Work Plan” aimed at enhancing Beijing’s service industry...

Company Deals

Bayer Partners with CrossBay Medical to Enhance Hormonal IUS Delivery System

Fineline Cube Dec 1, 2023

Germany’s Bayer (ETR: BAYN) has announced a strategic partnership with women’s health innovator CrossBay Medical...

Company Deals

Johnson & Johnson Acquires Laminar for $400 Million to Enhance Heart Rhythm Solutions

Fineline Cube Dec 1, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has finalized the acquisition of medical device manufacturer Laminar...

Company Drug

Yingli Pharma Enrolls First Patient in Phase I Study for KRAS Inhibitor YL-17231 at MD Anderson

Fineline Cube Dec 1, 2023

Yingli Pharma, a US-based biopharmaceutical company focused on developing therapies for both the Chinese and...

Company Deals

MSD to Migrate IT Systems to AWS, Aiming for Faster Drug Discovery and Clinical Trials

Fineline Cube Dec 1, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced plans to transition a significant portion...

Company Drug

Akeso’s AK111 Achieves Key Efficacy Milestones in Phase III Trial for Plaque Psoriasis

Fineline Cube Dec 1, 2023

Akeso Biopharma (HKG: 9926), based in China, has announced that its pivotal Phase III clinical...

Company Drug

Sichuan Kelun-Biotech to Present Promising Phase II Results for SKB264 in mTNBC at SABCS 2023

Fineline Cube Dec 1, 2023

Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...

Company Drug

TG ImmunoPharma Secures U.S. FDA IND Approval for Promising mAb TGI-5 Targeting Multiple Cancers

Fineline Cube Dec 1, 2023

TG ImmunoPharma Co., Ltd, based in China, has announced that it has received Investigational New...

Company Drug

Insilico Medicine Launches Clinical Study for First-in-Class PHD Inhibitor ISM5411 in IBD

Fineline Cube Dec 1, 2023

Insilico Medicine, a China-based biotech leveraging generative artificial intelligence (AI), has announced the initiation of...

Company Drug

Simcere Secures NMPA Approval for Edaravone Sublingual Tablets Targeting Post-Stroke Cognitive Impairment

Fineline Cube Dec 1, 2023

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has received clinical trial approval from the National...

Company Drug

Everest Medicines Reports Positive Phase III Results for Velsipity in Ulcerative Colitis

Fineline Cube Dec 1, 2023

Everest Medicines (HKG: 1952), based in China, has announced positive topline results from a multi-center...

Company Medical Device

Acotec Secures FDA IDE Approval for AcoArt Litos Paclitaxel-Coated Balloon Catheter

Fineline Cube Dec 1, 2023

Acotec Scientific Holdings Ltd (HKG: 6669), based in China, has received Investigational Device Exemption (IDE)...

Company Deals

Perpetual Medicines Launches with $8 Million Seed Round, Led by Chengwei Capital

Fineline Cube Dec 1, 2023

Perpetual Medicines, a biotech firm with operations in Shanghai and Boston, has officially launched, announcing...

Company R&D

Takeda Reinforces Takeda Spark Incubator Program with Expanded Partnerships in China

Fineline Cube Nov 30, 2023

Takeda (TYO: 4502) has reportedly renewed and expanded a series of partnerships to bolster its...

Company

Novocure Restructures and Prioritizes Pipeline Amid Anticipated NSCLC Approval

Fineline Cube Nov 30, 2023

Novocure (NASDAQ: NVCR), a Switzerland-based developer of Tumor Treating Fields (TTFields) cancer therapeutic technology that...

Company Drug

AbbVie’s Telisotuzumab-Vedotin Shows Promising Results in NSCLC Phase 2 Trial

Fineline Cube Nov 30, 2023

AbbVie (NYSE: ABBV) has unveiled data from a Phase 2 trial of its potential first-in-class...

Company Deals

Boehringer Ingelheim Partners with Phenomic AI to Target Stroma-Rich Cancers

Fineline Cube Nov 30, 2023

Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Canada’s Phenomic...

Posts pagination

1 … 419 420 421 … 650

Recent updates

  • GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors
  • Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M
  • Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration
  • Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History
  • Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors

Company Deals

Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M

Company Deals

Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration

Company Drug

Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.